Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Do thiazolidinediones increase the risk of congestive heart failure and cardiovascular death?

Nature Clinical Practice Endocrinology & Metabolism volume 4, pages 260–261 (2008)Cite this article

boxed-textLago RM et al. (2007) Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials. Lancet 370: 1129–1136

Background

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Home PD et al. (2007) Rosiglitazone evaluated for cardiovascular outcomes—an interim analysis. N Engl J Med 357: 28–38

    Google Scholar 

  2. Erdmann E et al. (2007) Pioglitazone use and heart failure in patients with type 2 diabetes and preexisting cardiovascular disease: data from the PROactive study (PROactive 08). Diabetes Care 30: 2773–2778

    Google Scholar 

  3. Nathan DM et al. (2008) Management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: update regarding the thiazolidinediones. Diabetologia 51: 8–11

    Google Scholar 

  4. The DREAM (Diabetes Reduction Assessment with Ramipril and Rosiglitazone Medication) Trial Investigators (2006) Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 368: 1096–1105

  5. Bolen S et al. (2007) Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus. Ann Intern Med 147:386–399

    Google Scholar 

Download references

Acknowledgements

The synopsis was written by Alexandra King, Associate Editor, Nature Clinical Practice.

Author information

Author notes

  1. Department of Medicine, Academic Hospital of Liège, CHU Sart Tilman (B35), B 4000 Liège, Belgium andre.scheen@chu.ulg.ac.be

Authors and Affiliations

  1. Department of Medicine, AJ Scheen is Head of the Diabetes, Nutrition and Metabolic Disorders Unit and of the Clinical Pharmacology Unit, the Academic Hospital of Liège, CHU Sart Tilman (B35), Liège, Belgium.,

    André J Scheen

Authors
  1. André J Scheen
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Competing interests

AJ Scheen was a member of the International Steering Committee of PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events). Dr Scheen is a consultant, lecturer and/or clinical researcher for AstraZeneca, Eli Lilly GlaxoSmithKline, Merck Sharp and Dohme, Merck-Santé, Novo Nordisk, Sanofi-Aventis, and Takeda.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Scheen, A. Do thiazolidinediones increase the risk of congestive heart failure and cardiovascular death?. Nat Rev Endocrinol 4, 260–261 (2008). https://doi.org/10.1038/ncpendmet0781

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpendmet0781

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing